Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome. [electronic resource]
Producer: 20110408Description: 976-83 p. digitalISSN:- 2567-689X
- Acute Coronary Syndrome -- blood
- Administration, Oral
- Adult
- Aged
- Aged, 80 and over
- Biomarkers -- blood
- Blood Coagulation -- drug effects
- Chi-Square Distribution
- Chromatography, Liquid
- Dose-Response Relationship, Drug
- Double-Blind Method
- Down-Regulation
- Enzyme-Linked Immunosorbent Assay
- Factor Xa -- metabolism
- Factor Xa Inhibitors
- Female
- Fibrin Fibrinogen Degradation Products -- metabolism
- Fibrinolytic Agents -- administration & dosage
- Humans
- International Normalized Ratio
- Male
- Middle Aged
- Odds Ratio
- Partial Thromboplastin Time
- Peptide Fragments -- blood
- Placebo Effect
- Prothrombin
- Pyrazoles -- administration & dosage
- Pyridones -- administration & dosage
- Tandem Mass Spectrometry
- Thrombin -- metabolism
- Time Factors
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.